The headline needs two separate verbs
A medicine might change craving without helping someone stop smoking. That distinction is the starting point for a small semaglutide study published in May 2026. The investigators observed reduced nicotine craving and body weight, but the study did not establish success on its primary laboratory smoking outcomes or reduced weekly cigarettes. I would not compress those results into a claim that semaglutide makes people quit. The interesting part is the research question; the practical limit is that a craving signal is not an established cessation treatment.[1]
Who entered the experiment
The phase 2a randomized study involved adults who smoked at least five cigarettes daily and were not seeking cessation treatment. Of 45 people enrolled, 24 were randomized, with 12 assigned to semaglutide and 12 to placebo. Treatment lasted nine weeks. That is a small, short experiment, not a large trial of a complete quit-smoking program. The study registration identifies the project as NCT05530577. When reading coverage, distinguish the people screened or enrolled from the people actually randomized; those denominators describe different stages of the research.[1]
What the trial measured
The investigators assessed smoking behavior in laboratory sessions and followed cigarette use and craving during treatment. The primary treatment-by-time results for laboratory smoking resistance and cigarette count were not statistically significant. Supplementary analyses and craving measurements offered signals worth investigating. That mix is exactly why I look for the stated primary outcome before reading a favorable sentence from a secondary analysis. A positive measurement is still a finding, but it should retain its place in the study rather than being promoted into proof of a different outcome.[1] Our research-reading checklist explains why the planned endpoint should lead the interpretation.
| Measure | Reported finding | Interpretation |
|---|---|---|
| Randomized participants | 24 total; 12 per group | Small phase 2a sample |
| Laboratory primary outcomes | No significant primary treatment-by-time effects | Did not establish primary laboratory benefit |
| Weekly cigarette use | No significant reduction established | Not proof of quitting |
| Nicotine craving | Reduced with semaglutide | A separate measure from abstinence |
Adults with daily cigarette use who were not seeking cessation treatment. Supplementary analyses do not replace the prespecified primary outcomes. Source: Hendershot et al.: randomized semaglutide trial in adults with daily cigarette use.
Why less craving is not the same as abstinence
Imagine a hypothetical participant who rates an urge lower but continues smoking each day. That person could improve on a craving scale without achieving abstinence. Conversely, a person may stop smoking while still experiencing strong urges. The two measures are related questions, not interchangeable records. I would want a cessation study to specify how quitting is defined, when it is assessed and how it is verified. Without those details, a headline about fewer cravings cannot tell a reader the probability of successfully stopping cigarettes.
Small studies leave large practical questions
The brief follow-up does not establish a durable quit rate, a long-term weight outcome after quitting or how semaglutide would perform alongside a standard cessation program. The paper’s authors call for larger trials. A treatment schedule used in a research protocol also should not be copied as self-treatment. Ask whether an article is discussing an experimental question, an approved indication or an individualized clinical decision. An investigator’s proposal for further research belongs in the first category, even when the mechanism sounds persuasive.[1] A related early research question appears in our semaglutide and alcohol-use trial review; results in one behavior do not prove results in another.
There are existing options for a quit-smoking discussion
FDA describes approved cessation products including nicotine replacement therapies and prescription medicines such as varenicline and bupropion. Their suitability and risks require their own discussion; the list is not a recommendation to combine them with a GLP-1 medicine. The key practical point is that someone who wants to stop smoking does not need to treat an exploratory semaglutide finding as their only option. Tell a clinician or pharmacist what you already take, what you have tried and what help you need to make a quit attempt.[3]
Ask about support, not just a prescription
CDC organizes guidance around using quit-smoking medicines correctly and choosing support appropriate to the person. For a clinical appointment, I would write down current tobacco use, past quit attempts and any concern about weight change. Keep a smoking goal distinct from an existing weight-management or diabetes goal so that neither gets lost. If a practice sells a GLP-1 program, ask which problems it actually manages and who will handle the cessation plan. Buying one service does not establish that the practice provides every kind of follow-up.[4] When evaluating a general care service, our Sesame Care review provides service and appointment questions; it is not evidence of a GLP-1 smoking-cessation program.
What would make the next study more useful
I would look for more participants, a defined cessation goal, a meaningful follow-up period and a clear distinction between primary and exploratory findings. The comparison treatment and counseling also matter: a study of a medicine alone asks a different question from adding it to a structured cessation program. Until stronger evidence answers those questions, the honest takeaway is limited. Semaglutide’s effect on smoking-related behavior is being investigated. This small trial offers a reason for further research, not a reason to replace an established quit-smoking discussion. A trial registration can help you check the originally stated outcomes, but registration itself is not a favorable result. Look for the completed report and its actual comparison before interpreting a research project as evidence that something works. For the broader appetite question, read food noise and GLP-1 evidence while keeping tobacco outcomes separate.
Continue your research
Sources & scope
Sources checked October 23, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- Hendershot et al.: randomized semaglutide trial in adults with daily cigarette use
- ClinicalTrials.gov: NCT05530577 study registration
- FDA: approved and cleared smoking-cessation products
- CDC: using quit-smoking medicines
Prices and terms can change. Confirm your specific offer directly with the provider.